FAMPAC
Marke : CLS Cell Lines Service
FAMPAC Cells
General information
Description | The Fampac cell line was established from the primary pancreatic adenocarcinoma of an adult female who had a familial predisposition to pancreatic cancer. These cells are epithelial in nature and have been utilized extensively in research focused on the biological behavior of pancreatic cancer, including studies on tumor progression, metastasis, and therapeutic response. The Fampac cell line is known for its aggressive tumor-forming capability in xenograft models, which makes it valuable for in vivo studies related to drug efficacy and cancer cell biology. In vitro, Fampac cells exhibit characteristics typical of pancreatic adenocarcinoma, including resistance to apoptosis and the ability to proliferate under chemically defined conditions. This resistance to programmed cell death is a critical feature for studies looking to explore new chemotherapeutic agents and their potential to induce cancer cell death. Additionally, Fampac cells have been used to study the molecular mechanisms of pancreatic cancer pathogenesis, offering insights into genetic mutations, signaling pathways involved in cancer proliferation, and interactions with the tumor microenvironment. |
---|---|
Organism | Human |
Tissue | Pancreas |
Disease | Adenocarcinoma |
Synonyms | FamPAC, Fampac, PA-CLS-13, PA-CLS 13 |
Characteristics
Age | 43 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | FAMPAC (Cytion catalog number 300309) |
---|---|
Biosafety level | 1 |
Depositor | Dr. Schmidt |
Expression / Mutation
Protein expression | p53, point mutation (CCG (Arg) to CAC (His) |
---|---|
Antigen expression | FAMPAC cells carry a homozygous Kras mutation in codon12: GGT(Gly) >GTT(Val) |
Tumorigenic | Yes, in nude mice, adenocarcinoma |
Karyotype | 45-48, x,+3,-5,+der(5),+der(5),+der(5)add(p14),-7,+10,+2der(10)add(p15)add(q26),der(12)add(p13),der(12)add(p11),-13,-13,+der(13)add(p11),-14,der?(14),-15,i(15q),der(16)(q+),-19,-20,-21,-22,+3-5mar |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 24 to 48 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:4 to 1:6 is recommended |
Seeding density | 1 x 10^4 cells/cm^2 will yield in a confluent layer in about 2to3 days |
Fluid renewal | 2 to 3 times per week |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,x CSF1PO: 10 D13S317: 8 D16S539: 14 D5S818: 10,11 D7S820: 11 TH01: 9 TPOX: 8 vWA: 15 D3S1358: 16,17 FGA: 32.2 D1S1656: 15 D6S1043: 12,13 D2S1338: 11 D12S391: 10,12 D19S433: 22 |
HLA alleles | A*: 03:01:01 B*: 27:05:02 C*: 15:02:01 DRB1*: 12:01:01 DQA1*: 05:05:01 DQB1*: 03:01:01 DPB1*: 03.01:01 E: 01:01:01 |